Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 EVOLVE Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018

Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 EVOLVE Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018. 82% overall response rate observed in heavily pre-treated patients. 9% of patients experienced grade 3/4 cytokine release syndrome; 7% experienced a grade 3/4 neurological event